𝔖 Bobbio Scriptorium
✦   LIBER   ✦

PCN113 PHARMACOECONOMIC ANALYSIS OF CAPECITABINE PLUS OXALIPLATIN (XELOX) VERSUS 5-FLUOROURACIL/LEUCOVORIN PLUS OXALIPLATIN (FOLFOX) IN THE FIRST LINE TREATMENT OF METASTASIS COLORECTAL CANCER IN TAIWAN

✍ Scribed by HH Chen; CS Chang; LT Chen; WT Chen; TC Hsu; JY Wang; CY Wen

Book ID
118611956
Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
81 KB
Volume
12
Category
Article
ISSN
1098-3015

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Capecitabine plus oxaliplatin (XELOX) ve
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer
✍ Michel Ducreux; Jaafar Bennouna; Mohamed Hebbar; Marc Ychou; GΓ©rard Lledo; Thier πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 French βš– 440 KB

## Abstract A regimen consisting of 5‐fluorouracil/leucovorin plus oxaliplatin (FOLFOX‐6) is widely used in France in the first‐line treatment of metastatic colorectal cancer (MCRC). The aim of our study was to demonstrate the non‐inferiority of capecitabine plus oxaliplatin (XELOX) __versus__ FOLF